Your session is about to expire
← Back to Search
Iberdomide Maintenance Therapy for Multiple Myeloma
Study Summary
This trial will study if a drug called iberdomide is safe and effective when given to people after they have a stem cell transplant to treat their myeloma. A maximum of 38 people will be enrolled.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am at least 18 years old, or 19 if I live in Nebraska.I have a type of blood cancer that doesn't produce typical markers.I can become pregnant and agree to use two forms of birth control or practice abstinence.I have been diagnosed with active Multiple Myeloma.My cancer was measurable by specific protein levels in my blood or urine at diagnosis.Within the past 14 days, you have had low levels of certain blood cells, high levels of calcium in your blood, or liver or kidney problems.I do not have severe nerve damage, major gut issues affecting drug absorption, or trouble swallowing pills.You have not started treatment for multiple myeloma within the past year, have not had disease progression after initial treatment, have not had a specific type of stem cell or organ transplant, and have a good performance status.Criterion: You have taken certain medications that weaken your immune system within the last 14 days, or you have used specific strong medications or herbs in the last two weeks. You also have a certain virus, hepatitis, or have taken a certain medication before.I agree to follow strict rules to prevent pregnancy and not donate sperm or blood while on and after the study treatment.I have been cancer-free for over 5 years, except for certain non-aggressive types.You have had a severe allergic reaction to thalidomide, lenalidomide, or pomalidomide in the past.My multiple myeloma has worsened after a stem cell transplant.I am pregnant, nursing, breastfeeding, or plan to become pregnant during the study.I haven't had major surgery, plasmapheresis, certain radiation therapies, or systemic myeloma treatments in the last 14 days.I have heart issues like recent heart attack, severe heart failure, or unstable angina.
- Group 1: Iberdomide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are investigators actively enrolling new participants for the clinical trial?
"According to clinicaltrials.gov, this medical research is presently recruiting participants with the original post date set at April 15th 2022 and most recent update being on April 27th of the same year."
Has Iberdomide been given the green light by the FDA?
"Our assessment of Iberdomide's safety, based on the Phase 2 trial data available, resulted in a score of two. This is due to limited evidence supporting efficacy and some data indicating its security profile."
How many individuals are being enlisted in this investigation?
"Affirmative. Details published on clinicaltrials.gov certify that this investigation, initially listed on April 15th 2022, is actively recruiting. 38 people need to be recruited from 1 trial site."
Share this study with friends
Copy Link
Messenger